| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
|
N Engl J Med
|
2003
|
7.25
|
|
2
|
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
|
N Engl J Med
|
2005
|
4.03
|
|
3
|
Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
|
Ann Intern Med
|
2011
|
2.96
|
|
4
|
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.
|
Am J Respir Crit Care Med
|
2010
|
2.60
|
|
5
|
Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass.
|
J Clin Endocrinol Metab
|
2004
|
2.36
|
|
6
|
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.
|
Endocr Pract
|
2011
|
2.29
|
|
7
|
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.
|
J Bone Miner Res
|
2008
|
1.82
|
|
8
|
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Bone
|
2012
|
1.79
|
|
9
|
Vitamin D status and response to Vitamin D(3) in obese vs. non-obese African American children.
|
Obesity (Silver Spring)
|
2008
|
1.69
|
|
10
|
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women.
|
Mayo Clin Proc
|
2010
|
1.62
|
|
11
|
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
|
J Bone Miner Res
|
2014
|
1.62
|
|
12
|
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
|
J Clin Endocrinol Metab
|
2008
|
1.53
|
|
13
|
The management of osteoporosis following hip fracture: have we improved our care?
|
Osteoporos Int
|
2003
|
1.52
|
|
14
|
A pilot study of heel ultrasound to screen for low bone mass in children with leukemia.
|
J Pediatr Hematol Oncol
|
2006
|
1.50
|
|
15
|
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).
|
J Clin Endocrinol Metab
|
2014
|
1.41
|
|
16
|
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women.
|
J Bone Miner Res
|
2012
|
1.29
|
|
17
|
Predicting fractures in an international cohort using risk factor algorithms without BMD.
|
J Bone Miner Res
|
2011
|
1.22
|
|
18
|
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW).
|
J Bone Miner Res
|
2014
|
1.19
|
|
19
|
SOLAR ultraviolet radiation and vitamin D: a historical perspective.
|
Am J Public Health
|
2007
|
1.09
|
|
20
|
Impact of season and diet on vitamin D status of African American and Caucasian children.
|
Clin Pediatr (Phila)
|
2011
|
1.09
|
|
21
|
Vitamin D insufficiency in preadolescent African-American children.
|
Clin Pediatr (Phila)
|
2005
|
1.07
|
|
22
|
An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW).
|
Ann Rheum Dis
|
2012
|
1.06
|
|
23
|
Physical function in men with prostate cancer on androgen deprivation therapy.
|
Phys Ther
|
2007
|
1.06
|
|
24
|
Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women.
|
J Am Geriatr Soc
|
2013
|
1.05
|
|
25
|
Quality of life in prostate cancer patients taking androgen deprivation therapy.
|
J Am Geriatr Soc
|
2006
|
1.04
|
|
26
|
Height loss, vertebral fractures, and the misclassification of osteoporosis.
|
Bone
|
2010
|
1.04
|
|
27
|
Skeletal integrity in patients with nail patella syndrome.
|
J Clin Endocrinol Metab
|
2004
|
0.98
|
|
28
|
Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.
|
Crit Rev Oncol Hematol
|
2008
|
0.96
|
|
29
|
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Bone
|
2011
|
0.96
|
|
30
|
Altered bone mass in children at diagnosis of Crohn disease: a pilot study.
|
J Pediatr Gastroenterol Nutr
|
2005
|
0.95
|
|
31
|
Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.
|
Bone
|
2012
|
0.95
|
|
32
|
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study.
|
J Bone Miner Res
|
2008
|
0.92
|
|
33
|
Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer.
|
J Clin Densitom
|
2011
|
0.92
|
|
34
|
Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
|
Urology
|
2008
|
0.91
|
|
35
|
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
|
J Bone Miner Res
|
2016
|
0.91
|
|
36
|
Plasma inflammatory mediators associated with bone metabolism in COPD.
|
COPD
|
2010
|
0.89
|
|
37
|
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.
|
Endocr Pract
|
2011
|
0.88
|
|
38
|
Factors associated with osteoporosis screening and recommendations for osteoporosis screening in older adults.
|
J Gen Intern Med
|
2009
|
0.88
|
|
39
|
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
|
J Clin Endocrinol Metab
|
2006
|
0.87
|
|
40
|
Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis.
|
J Clin Endocrinol Metab
|
2011
|
0.86
|
|
41
|
Health Beliefs about Osteoporosis and Osteoporosis Screening in Older Women and Men.
|
Health Educ J
|
2010
|
0.85
|
|
42
|
A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis.
|
Eur J Endocrinol
|
2012
|
0.85
|
|
43
|
Thigh muscle strength in senior athletes and healthy controls.
|
J Strength Cond Res
|
2009
|
0.84
|
|
44
|
Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Calcif Tissue Int
|
2014
|
0.83
|
|
45
|
Bisphosphonates and osteonecrosis of the jaw.
|
Ann Intern Med
|
2006
|
0.81
|
|
46
|
Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis?
|
J Clin Densitom
|
2003
|
0.80
|
|
47
|
Heel ultrasound can assess maintenance of bone mass in women with breast cancer.
|
J Clin Densitom
|
2012
|
0.80
|
|
48
|
Impact of seasonal flux on 25-hydroxyvitamin D and bone turnover in pre- and early pubertal youth.
|
Pediatr Int
|
2014
|
0.80
|
|
49
|
Associations between bone mineral density, grip strength, and lead body burden in older men.
|
J Am Geriatr Soc
|
2014
|
0.80
|
|
50
|
The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.
|
J Urol
|
2007
|
0.78
|
|
51
|
Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
|
PLoS One
|
2012
|
0.78
|
|
52
|
Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
|
J Clin Endocrinol Metab
|
2009
|
0.77
|
|
53
|
Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women.
|
Maturitas
|
2007
|
0.77
|
|
54
|
Osteoporosis screening preferences of older adults.
|
J Clin Densitom
|
2009
|
0.76
|
|
55
|
Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis.
|
Clin Endocrinol (Oxf)
|
2013
|
0.75
|
|
56
|
Competitive athletic participation, thigh muscle strength, and bone density in elite senior athletes and controls.
|
J Strength Cond Res
|
2013
|
0.75
|
|
57
|
Vignettes in osteoporosis: a road map to successful therapeutics.
|
J Bone Miner Res
|
2004
|
0.75
|